NVS vs REGN
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases.
Side-by-side fundamentals
| Metric | NVS | REGN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $156.11 | $667.17 | |
| Market cap as of 2026-08-01 | $232.1B | $62.7B | |
| P/E as of 2026-08-01 | 22.48 | 17.49 | REGN lower |
| PEG as of 2026-08-01 | 3.66 | 1.08 | REGN lower |
| Net margin as of 2026-08-01 | +22.5% | +29.6% | REGN higher |
| Gross margin as of 2026-08-01 | +75.0% | +85.7% | REGN higher |
| Operating margin as of 2026-08-01 | +29.9% | +24.3% | NVS higher |
| ROE as of 2026-08-01 | +29.9% | +14.3% | NVS higher |
| ROA as of 2026-08-01 | +11.1% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-01 | 1.18 | 0.09 | REGN lower |
| Revenue growth (YoY) as of 2026-08-01 | +3.3% | +5.9% | REGN higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.6% | |
| Dividend yield as of 2026-08-01 | +2.9% | +0.5% | NVS higher |
| Beta as of 2026-08-01 | 1.17 | 0.19 | |
| 1-year return as of 2026-07-27 close | +32.6% | +18.5% | NVS higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.